L
Lance D. Miller
Researcher at Wake Forest University
Publications - 208
Citations - 16169
Lance D. Miller is an academic researcher from Wake Forest University. The author has contributed to research in topics: Cancer & Breast cancer. The author has an hindex of 58, co-authored 195 publications receiving 14459 citations. Previous affiliations of Lance D. Miller include University of Texas MD Anderson Cancer Center & East Carolina University.
Papers
More filters
Patent
Methods of controlling tumorigenesis and diagnosing the risk thereof
TL;DR: In this article, the authors present methods of treatment, prevention and diagnosis of neoblastoma, including cancer, such as metastatic cancer, which is a type of brain tumor.
Proceedings ArticleDOI
Abstract A25: Yin Yang 1 promotes AKT activation through direct protein binding
Qiang Zhang,Meimei Wan,David A. Horita,Lance D. Miller,Steven J. Kridel,Timothy E. Kute,George Kulik,Guangchao Sui +7 more
TL;DR: A PI3K-independent mechanism of mTORC2-mediated AKT activation stimulated by YY1 binding to its PH domain is discovered, which supports the proliferative role of YY 1 in mammary oncogenesis.
Journal ArticleDOI
Immune gene signatures and tumor intrinsic markers delineate novel immunogenic subtypes of breast cancer
Lance D. Miller,Jeff W. Chou,Michael A. Black,Cristin G. Print,Eric B. Jimenez,Julia Chifman,Angela Tatiana Alistar,Thomas C. Putti,Xiaobo Zhou,Davide Bedognetti,Ashok K. Pullikuth,Eran R. Andrechek,Ena Wang,Francesco M. Marincola +13 more
TL;DR: It is concluded that breast tumors can be dichotomized into two subtypes fundamentally distinct with respect to their potential for metastasis-protective immune responsiveness, and new contexts for studying anti-tumor immunity and oncogenic mechanisms of immunosuppression in breast cancer.
Posted ContentDOI
Conditional activation of immune-related signatures and prognostic significance: a pan-cancer analysis
Jessica Roelands,Wouter Hendrickx,Raghvendra Mall,Mohamad Saad,Kyle Halliwill,Gabriele Zoppoli,Giuseppe Curigliano,Giuseppe Curigliano,Darawan Rinchai,Julie Decock,Julie Decock,Lucia Gemma Delogu,Lotfi Chouchane,Ena Wang,Peter J. K. Kuppen,Pascal Finetti,François Bertucci,Lance D. Miller,Jérôme Galon,Francesco M. Marincola,Michele Ceccarelli,Davide Bedognetti +21 more
TL;DR: A relationship was observed between the enrichment of oncogenic pathways and the prognostic significance of the ICR and its predictive value for patients treated with anti-CTLA4 immune checkpoint inhibition, and this conditional impact of ICR was also validated in the context of immune checkpoints inhibition treatment.
Journal ArticleDOI
Identifying Driver Genes in Cancer by Triangulating Gene Expression, Gene Location, and Survival Data
TL;DR: This refined version of TRIAGE allowed us to identify known prominent driver genes, such as MMP1, IL8, and COL1A2, but it also led to identify several novel ones, which could perhaps elucidate potential future targets of novel anticancer therapeutics.